Pioglitazone

Generic Name: Pioglitazone

Brand Names: Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₀N_₂O_₃S

CAS Number: 111025-46-8

Unique Ingredient Identifier: X4OV71U42S

Background: Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...

Indication: Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.

Associated Conditions: Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Pioglitazone

First Posted Date: 2014-02-21

Last Posted Date: 2019-03-12

Lead Sponsor: Takeda

Target Recruit Count: 1067

Registration Number: NCT02068508

Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes Patients

Not Applicable

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Metformin
Drug: Pioglitazone

First Posted Date: 2014-01-03

Last Posted Date: 2014-01-03

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 102

Registration Number: NCT02027103

Locations: 🇮🇷
Diabetes Clinic, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Pioglitazone

First Posted Date: 2013-12-06

Last Posted Date: 2019-01-24

Lead Sponsor: Takeda

Target Recruit Count: 18223

Registration Number: NCT02002975

Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Biguanides / Long-term Treatment"

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Pioglitazone

First Posted Date: 2013-12-06

Last Posted Date: 2016-11-10

Lead Sponsor: Takeda

Target Recruit Count: 899

Registration Number: NCT02003014

Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy

Phase 4

Completed

Conditions: Type II Diabetes Mellitus

Interventions: Drug: Pioglitazone
Drug: Metformin
Drug: Sulfonylurea

First Posted Date: 2013-10-30

Last Posted Date: 2018-09-12

Lead Sponsor: Takeda

Target Recruit Count: 114

Registration Number: NCT01972724

Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients

Not Applicable

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Metformin
Drug: Pioglitazone

First Posted Date: 2013-10-16

Last Posted Date: 2013-10-16

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 84

Registration Number: NCT01963663

Locations: 🇮🇷
Diabetes Clinic, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"

Completed

Conditions: Bladder Cancer

Interventions: Drug: Pioglitazone

First Posted Date: 2013-09-05

Last Posted Date: 2022-01-25

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 6107

Registration Number: NCT01935466

Locations: 🇮🇳
Deptt of Endocrinology, Chandigarh, India

Effect of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders

Interventions: Drug: Pioglitazone
Drug: Metformin

First Posted Date: 2013-09-05

Last Posted Date: 2014-06-17

Lead Sponsor: King Abdulaziz University

Target Recruit Count: 440

Registration Number: NCT01935804

Locations: 🇸🇦
Center of Excellence for Osteoporosis Research, King Abdulaziz University, Jeddah, Makkah, Saudi Arabia

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

Phase 3

Terminated

Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions: Drug: Pioglitazone placebo
Drug: Pioglitazone

First Posted Date: 2013-08-29

Last Posted Date: 2019-09-16

Lead Sponsor: Takeda

Target Recruit Count: 3494

Registration Number: NCT01931566

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Phase 1

Completed

Conditions: Castration Resistant Prostate Cancer (CRPC)
Pharmacokinetics of MDV3100

Interventions: Drug: MDV3100
Drug: Pioglitazone
Drug: Warfarin
Drug: Omeprazole
Drug: Midazolam

First Posted Date: 2013-07-30

Last Posted Date: 2017-06-26

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 14

Registration Number: NCT01911728

Locations: 🇿🇦
Parexel, George, South Africa
🇿🇦
Parexel/Qdot Pharma, Port Elizabeth, South Africa

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy